Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name MGD019
Synonyms
Therapy Description

MGD019 is a tetravalent, dual-affinity re-targeting (DART) protein that potentially inhibits PD-1 (PDCD1) and CTLA4, resulting in enhanced immune response against cancer cells expressing PD-1 and CTLA4 (Keystone Symposia Conference, 2019, Feb. 18-22, Abs nr: 1012).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
MGD019 MGD-019|MGD 019|AEX-1344|AEX1344|lorigerlimab CTLA4 Inhibitor 4 Immune Checkpoint Inhibitor 149 MGD019 is a tetravalent, dual-affinity re-targeting (DART) protein that potentially inhibits PD-1 (PDCD1) and CTLA4, resulting in enhanced immune response against cancer cells expressing PD-1 and CTLA4 (Keystone Symposia Conference, 2019, Feb. 18-22, Abs nr: 1012).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT05475171 Phase II MGD019 Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION) Recruiting USA 0
NCT03761017 Phase I MGD019 MGD019 DART Protein in Unresectable/Metastatic Cancer Active, not recruiting USA | POL | ESP | BGR 1


Additional content available in CKB BOOST